Please login to the form below

Not currently logged in
Email:
Password:

Sanofi and Lexicon collaborate on new medication for diabetes

Plan to develop new investigational drugsotagliflozin

Sanofi

Sanofi and Lexicon Pharmaceuticals have agreed to collaborate in the development and commercialisation of sotagliflozin, an investigational new drug for diabetes.

Sotagliflozin is a new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), currently being studied in two pivotal phase III trials in type 1 diabetes. Phase III trials in type 2 diabetes are set to begin in 2016.

Pascale Witz, executive VP at Sanofi, said: “This agreement with Lexicon reinforces our commitment to helping people living with diabetes.

“Adding sotagliflozin to our portfolio, which includes medicines at virtually every stage of the treatment pathway, highlights our focus on providing a large and diverse set of therapeutic options for people with this disease.”

Sotagliflozin has previously shown encouraging results in phase II studies for type 1 diabetes, including reduction of blood sugar (HBA1C) improvement in glycaemic variability and reduced mealtime insulin dose compared with placebo.

Phase II studies exploring treatment in people with type 2 diabetes, including those with renal impairment, showed lowering of blood sugar (HbA1c), weight loss and blood pressure improvements. No increase in hypoglycaemic events was seen with sotagliflozin compared to background therapy.

Under the terms of the agreement, Lexicon will receive an upfront payment of $300m and is eligible to receive development, regulatory and sales milestone payments of up to $1.4bn.

Lexicon is also entitled to royalties on net sales of sotaglifozin and will share in the funding of a portion of the planned type 2 diabetes development costs over the next three years up to an aggregate of $100m.

Sanofi will be responsible for all clinical development and commercialisation activities of sotagliflozin for the treatment of type 2 diabetes around the world and will also be responsible for the commercialisation of sotagliflozin for type 1 diabetes outside the US.

Last week Sanofi also agreed to a collaboration with Korean-firm Hanmi to develop a portfolio of experimental, long-acting diabetes treatments.  

Article by
Nikhil Patel

9th November 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hayward Medical Communications

Hayward Medical Communications has been supporting partners in every sector of the healthcare industry to deliver evidence-based, clinically relevant and...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics